- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06141941
Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes
Study Overview
Detailed Description
This is a prospective cohort study of women with type 1 and type 2 diabetes in the postpartum period. After obtaining informed consent, a CGM device (Dexcom sensor and transmitter) will be placed by research personnel upon presentation to labor or in prenatal clinic if seen within 3 days of planned induction of labor or planned cesarean section. Patient will be assisted in getting the Dexcom G6 app on their cell phone to be the receiver of glucose data. Patients who are currently using the Dexcom CGM for routine monitoring of their glucoses, will be allowed to continue using their own sensor and transmitter. Upon presentation to Labor and Delivery, patients will be assisted in activating the Share App on their cell phone. Labor and Delivery Nursing Staff will be given a Samsun phone with the Follow app in order to receive glucose data. The Samsung phone will be transferred to the Mother/Baby Unit with the patient after delivery.
Glucose values from the CGM device will then be available to nursing through the Samsung phone. Nursing will be able to see current glucose data on their patient and would receive alarms to indicate hypoglycemia or impending hypoglycemia. Nursing will be provided with instructions for how to access the CGM follow app and how to appropriately respond to the alarms. Nursing will continue to perform standard of care blood glucose monitoring per routine protocol but will also obtain a finger stick to validate a blood glucose level whenever a low CGM alarm sounds. Low blood glucose values <70 mg/dl will be treated per local institutional nursing policy. Monitoring of glucose levels through the CGM device will continue throughout their postpartum hospital stay. This is typically 2 days for a vaginal delivery, 3 days for a cesarean section. Patients who do not use CGM as part of their routine care, will have their CGM sensor and transmitter removed prior to discharge from the hospital.
Following discharge from the hospital, there will be no additional long term follow-up.
Data we plan to collect for analysis includes: type of diabetes (DM1/DM2), point of care glucose values, number of hypoglycemic events, number of times treated for hypoglycemia.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrea Greiner, MD
- Phone Number: +1 319 356 3180
- Email: andrea-greiner@uiowa.edu
Study Contact Backup
- Name: Annemarie Gilley, MD
- Phone Number: 3193563180
- Email: annemarie-gilley@uiowa.edu
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics
-
Contact:
- Andrea L Greiner, MD
- Phone Number: 319-356-3180
- Email: andrea-greiner@uiowa.edu
-
Contact:
- Annemarie Gilley, MD
- Phone Number: 3193563180
- Email: andrea-greiner@uiowa.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion:
1- Individuals in the third trimester of pregnancy admitted to the hospital with diabetes type 1 or diabetes type 2, own a smart device (which will serve as a receiver for the CGM device)
Exclusion:
- Patients less than 18 years of age
- non-English speaking patients
- gestational diabetes
- extensive skin changes/diseases that inhibit wearing a sensor on normal skin, known allergy to adhesives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: CGM
A CGM device (Dexcom sensor and transmitter) will be placed by research personnel upon presentation to Labor and Delivery unit.
|
Continuous glucose monitoring
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose values
Time Frame: Postpartum admission, 2-4 days
|
glucose values obtained from CGM application
|
Postpartum admission, 2-4 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrea Greiner, MD, University of Iowa OBGYN
Publications and helpful links
General Publications
- Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, Asztalos E, Barrett JFR, Sanchez JJ, de Leiva A, Hod M, Jovanovic L, Keely E, McManus R, Hutton EK, Meek CL, Stewart ZA, Wysocki T, O'Brien R, Ruedy K, Kollman C, Tomlinson G, Murphy HR; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25;390(10110):2347-2359. doi: 10.1016/S0140-6736(17)32400-5. Epub 2017 Sep 15. Erratum In: Lancet. 2017 Nov 25;390(10110):2346.
- Singh LG, Satyarengga M, Marcano I, Scott WH, Pinault LF, Feng Z, Sorkin JD, Umpierrez GE, Spanakis EK. Reducing Inpatient Hypoglycemia in the General Wards Using Real-time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial. Diabetes Care. 2020 Nov;43(11):2736-2743. doi: 10.2337/dc20-0840. Epub 2020 Aug 5.
- Spanakis EK, Levitt DL, Siddiqui T, Singh LG, Pinault L, Sorkin J, Umpierrez GE, Fink JC. The Effect of Continuous Glucose Monitoring in Preventing Inpatient Hypoglycemia in General Wards: The Glucose Telemetry System. J Diabetes Sci Technol. 2018 Jan;12(1):20-25. doi: 10.1177/1932296817748964. Epub 2017 Dec 13.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202101006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregestational Diabetes
-
Sheba Medical CenterUnknownPregestational DiabetesIsrael
-
University of RochesterCompletedGestational Diabetes | Pregestational DiabetesUnited States
-
The University of Texas Health Science Center,...Active, not recruiting
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Hadassah Medical OrganizationUnknownGestational Diabetes | Epigenetic Changes | Pregestational Diabetes | Neurodevelopmental Outcome | IDM (Infant of Diabetic Mothers)Israel
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Ankara City Hospital BilkentNot yet recruitingHearing Loss | Gestational Diabetes | Pregestational DiabetesTurkey
-
Instituto Nacional de Perinatologia Isidro Espinosa...National Council of Science and Technology, MexicoCompletedPregestational Obesity (BMI > 27kg/m2) | History of Polycystic Ovary SyndromeMexico
-
Centre Hospitalier Universitaire VaudoisCompletedPregnancy | Pregestational Diabetes | Polycystic Ovary Syndrom
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
Clinical Trials on CGM
-
Jaeb Center for Health ResearchDexCom, Inc.Completed
-
University Hospital PadovaBoston Children's Hospital; University of PadovaCompletedInfant, Very Low Birth Weight | Neonatal HypoglycemiaUnited States, Italy
-
University of Ljubljana, Faculty of MedicineCompleted
-
DexCom, Inc.Jaeb Center for Health ResearchCompletedDiabetes MellitusUnited States, Canada
-
Joslin Diabetes CenterDexCom, Inc.CompletedHypoglycemia | Hypoglycemia, ReactiveUnited States
-
Emory UniversityCompletedEnd Stage Kidney DiseaseUnited States
-
Intermountain Health Care, Inc.AbbottActive, not recruitingDiabetes Mellitus, Type 2United States
-
DexCom, Inc.CompletedDiabetes MellitusUnited States
-
Becton, Dickinson and CompanyCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed